Elamipretide (SS-31) Research: Cardiolipin Biology, Human Trials, and FDA Approval

The short version

Elamipretide is a synthetic, mitochondria-targeting tetrapeptide also known as SS-31 and MTP-131. It interacts with cardiolipin-rich mitochondrial membranes and has been studied in cell systems, isolated mitochondria, animal models, and multiple human disease programs.

The evidence is not one uniformly positive story. A small randomized crossover study in Barth syndrome missed its original primary endpoints, longer open-label observations produced a muscle-strength signal, and a 218-participant phase 3 trial in primary mitochondrial myopathy did not improve its two primary outcomes. Different populations, endpoints, and trial designs produced different answers.

FDA granted accelerated approval to Forzinity, a specific elamipretide drug product, on September 19, 2025 to improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kilograms. That narrow, product-specific approval does not establish broad effectiveness across mitochondrial disease and does not transfer to bulk powder or research-market vials.

Identity: SS-31, MTP-131, and elamipretide

SS-31 and MTP-131 are development names associated with elamipretide. FDA's approved label describes elamipretide hydrochloride as a mitochondrial cardiolipin binder with the chemical name L-phenylalaninamide, D-arginyl-2,6-dimethyl-L-tyrosyl-L-lysyl-, hydrochloride (1:3). The active peptide contains four residues, including D-arginine and the nonstandard residue 2,6-dimethyltyrosine, and ends in a phenylalanine amide.

Those details are not optional naming trivia. Residue stereochemistry, the dimethyltyrosine modification, C-terminal amidation, and salt form help define the represented material. A generic four-residue mass or the label SS-31 alone is not a complete identity specification.

FDA's Forzinity record concerns elamipretide hydrochloride in a defined finished product. Research catalogs may list elamipretide, SS-31, hydrochloride, acetate, or trifluoroacetate forms. Those entries should not be treated as analytically interchangeable without composition and counterion evidence.

Cell and membrane research: what cardiolipin binding shows

Cardiolipin is an anionic phospholipid concentrated in the inner mitochondrial membrane. It contributes to cristae organization and the membrane environment in which oxidative-phosphorylation proteins operate. Elamipretide's positive charge and aromatic features favor interaction with negatively charged membrane interfaces.

A 2020 biophysical study using model membranes, mitochondrial membranes, spectroscopy, and computational methods found that SS-31 partitioned into membrane interfaces in a surface-charge-dependent manner, changed lipid packing without disrupting the bilayer, and altered interfacial electrostatics. The authors proposed several nonexclusive ways those effects could influence mitochondrial proteins and ions.

This work supports a membrane-interaction mechanism under defined experimental conditions. It does not establish one exclusive molecular target, prove that every disease phenotype is driven by cardiolipin, or predict a clinical outcome from a binding assay.

• Biophysical result: interaction with charged lipid interfaces
• Cellular or organelle result: a change measured in isolated systems
• Animal result: tissue or whole-organism response in a defined model
• Human result: an endpoint in a specified population and trial
• Supplier result: analytical evidence concerning one sample or lot

Animal evidence: mitochondrial effects are model-specific

A frequently cited renal-ischemia study reported that SS-31 interacted with cardiolipin, reduced cytochrome-c peroxidase activity in experimental systems, preserved mitochondrial cristae, limited swelling, and accelerated ATP recovery in rats after ischemia and reperfusion.

That study connects a membrane interaction to organelle structure and a tissue-level outcome in one injury model. It provides a plausible bridge between mechanism and physiology, but it remains an animal experiment with model-specific timing, exposure, endpoints, and pathology.

The broader preclinical literature covers cardiac, renal, skeletal-muscle, metabolic, and aging-related models. Breadth across models can generate hypotheses; it does not convert all mitochondrial dysfunction into one treatable condition or establish human benefit.

Barth syndrome: the randomized trial and open-label extension

Barth syndrome is a rare, X-linked mitochondrial disorder caused by TAZ variants and abnormal cardiolipin remodeling. SPIBA-201 enrolled 12 participants at one U.S. site in a randomized, double-blind, placebo-controlled crossover study followed by an open-label extension.

The randomized part did not meet either original primary endpoint: six-minute walk distance or the Barth Syndrome Symptom Assessment total-fatigue score. Ten participants entered the open-label extension, and eight reached the published 36-week analysis. Improvements were reported in walking distance, symptom score, knee-extensor strength, and selected secondary measures during the extension.

The extension cannot provide the same protection against placebo effects, time effects, regression to the mean, selective continuation, and other bias as a blinded randomized comparison. The observations were important enough to inform later regulatory analysis, but the randomized and open-label evidence should not be blended into one undifferentiated claim.

Primary mitochondrial myopathy: a larger negative phase 3 trial

MMPOWER-3 randomized 218 participants with genetically confirmed primary mitochondrial myopathy to elamipretide or placebo for 24 weeks. The co-primary outcomes were change in six-minute walk distance and change in a patient-reported fatigue score.

The study did not meet either primary endpoint. The between-group difference in six-minute walk distance was minus 3.2 meters, with a confidence interval spanning benefit and harm, and the fatigue comparison was also not statistically significant. The publication classified the trial as Class I evidence that elamipretide did not improve those outcomes in that population over 24 weeks.

A negative trial does not prove that the molecule has no biological activity in every context. It does show why mitochondrial mechanism, animal results, and one rare-disease program cannot justify a general claim across heterogeneous mitochondrial myopathies.

Other human programs do not create a universal indication

Elamipretide has also been studied in cardiovascular, renal, ophthalmic, and metabolic contexts. For example, heart-failure trials evaluated short-term functional and imaging outcomes in relatively small populations. Results differed by endpoint and study design.

These programs are useful for understanding exposure, tolerability, and disease-specific hypotheses. They do not expand Forzinity's approved indication and should not be pooled casually with Barth syndrome or primary mitochondrial myopathy evidence.

The correct unit of interpretation is the particular trial: its population, test article, comparator, duration, endpoint hierarchy, missing-data approach, and prespecified analysis. A shared word such as mitochondrial is not enough to merge unlike diseases.

Why FDA granted accelerated approval

FDA initially issued a Complete Response letter in May 2025, citing a manufacturing-facility deficiency and concluding that the submitted records did not establish effectiveness for traditional approval or support the proposed surrogate endpoints for accelerated approval. FDA also identified knee-extensor muscle strength as a potentially reasonable intermediate clinical endpoint.

After the sponsor's complete response, FDA granted accelerated approval on September 19, 2025. The approved label states that the indication is supported by improvement in knee-extensor strength observed in an open-label extension that included seven pediatric participants aged 12 years and older.

Accelerated approval allows FDA to act on a surrogate or intermediate clinical endpoint reasonably likely to predict clinical benefit in a serious condition with unmet need. Continued approval may depend on verification and description of clinical benefit in a confirmatory trial. It is an approval, but its evidentiary basis and postapproval obligation should be described accurately.

FDA approval is narrow and product-specific

Forzinity is FDA approved to improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kilograms. The approval does not cover primary mitochondrial myopathy generally, heart failure, kidney injury, aging, athletic performance, fatigue in people without Barth syndrome, or every condition involving mitochondrial biology.

The approval package includes a defined hydrochloride active ingredient, finished formulation, manufacturing controls, specifications, stability program, labeling, and pharmacovigilance obligations. A supplier vial called SS-31 or elamipretide is not Forzinity merely because the names refer to the same active-moiety family.

Likewise, an FDA approval is not lot authentication. It cannot prove that a research sample contains the stated molecule, amount, stereochemistry, salt, impurity profile, or microbiological quality.

Safety evidence also has boundaries

FDA's label identifies administration-site reactions as common and includes warnings concerning serious hypersensitivity and benzyl-alcohol exposure in certain pediatric patients. The approved product's safety information reflects its specific formulation, studied populations, and regulatory record.

The clinical database remains small for Barth syndrome because the disease is ultrarare. Uncommon or delayed events may be difficult to characterize from a 12-person pivotal program, even with supportive safety observations from other disease studies.

Research-vial risk can include issues not measured by the clinical program: incorrect identity or quantity, stereochemical error, residual solvents, counterion differences, degradation, microbial contamination, endotoxin, and unsupported storage claims. Clinical tolerability cannot substitute for lot-level quality evidence.

Scientific evidence and supplier documentation answer different questions

A paper can show what characterized elamipretide did in a membrane system, rat model, or human trial. Supplier documentation asks whether a current lot is the chemical entity, form, amount, and quality represented. Those are separate evidence streams.

A mass spectrum consistent with elamipretide can support an identity claim when expected and observed ions, method, sample, and lot are coherent. It cannot prove mitochondrial benefit, clinical safety, FDA equivalence, sterility, or correct absolute content. A chromatographic area percentage likewise does not establish the entire structure or finished-product equivalence.

The phrase research use only is an intended-use statement. It does not mean FDA approved, pharmaceutical grade, sterile, clinically equivalent, or independently tested.

Analytical questions for elamipretide research material

Elamipretide is short, but its identity is not trivial. Documentation should specify residue order, D-arginine stereochemistry, 2,6-dimethyltyrosine, lysine, C-terminal phenylalaninamide, and the stated salt or counterion form. A method that only checks nominal mass may not distinguish every stereochemical or closely related structural error.

Mass spectrometry, retention behavior, amino-acid or sequence-aware analysis, and reference standards can contribute different information. No single headline number establishes identity, purity, absolute peptide content, water, counterion, residual solvents, aggregation, sterility, endotoxin, and stability simultaneously.

Due diligence should connect the product label, sample identifier, lot, specification, method, raw or interpretable output, expected result, observed result, reviewer, and date. Untested attributes should remain recorded as not reported rather than converted into assumed passes.

• Complete tetrapeptide identity and residue stereochemistry
• 2,6-dimethyltyrosine and C-terminal amide
• Hydrochloride, acetate, trifluoroacetate, or other stated form
• Lot-matched identity, chromatographic purity, and quantitative content reported separately
• Water, counterion, residual-solvent, degradation, and aggregation evidence where claimed
• Separate sterility and endotoxin testing for any claim involving those attributes
• No claim of equivalence to Forzinity without a finished-product-level evidence package

Limitations and unresolved questions

The exact relationship between membrane electrostatics, cardiolipin interaction, mitochondrial structure, and disease-specific human outcomes remains incomplete. Several mechanisms may operate together, and effects can differ with cell type, disease biology, and exposure.

The pivotal Barth evidence involves an ultrarare disease, a single site, very small numbers, missed randomized primary endpoints, and a strength signal from an open-label extension. Accelerated approval addresses unmet need while leaving confirmatory uncertainty explicit.

The negative MMPOWER-3 trial limits broad extrapolation, while other programs remain condition- and endpoint-specific. Future confirmatory Barth data, longer follow-up, replication, and postmarket safety information may change the evidence picture.

FAQ: Is SS-31 the same as elamipretide?

SS-31 is a research and development name associated with elamipretide; MTP-131 is another development identifier. A catalog name still does not prove exact stereochemistry, terminal chemistry, salt form, quantity, or equivalence to the approved Forzinity product.

FAQ: Is elamipretide FDA approved?

Yes, but the answer must remain product- and indication-specific. FDA granted accelerated approval to Forzinity in September 2025 to improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kilograms. The approval does not apply to unrelated supplier materials or other mitochondrial conditions.

FAQ: Did the human trials all succeed?

No. The randomized part of the small Barth study missed its original primary endpoints, while its open-label extension produced the intermediate muscle-strength signal used for accelerated approval. The larger MMPOWER-3 trial in primary mitochondrial myopathy did not meet either primary endpoint.

FAQ: Does 99% HPLC purity show a vial is equivalent to Forzinity?

No. An HPLC area result under one method does not establish complete identity, stereochemistry, peptide content by mass, salt composition, formulation, sterility, stability, manufacturing controls, or equivalence to an FDA-approved finished product.

The defensible conclusion

Elamipretide has a well-developed mechanistic and clinical record for a research peptide, but that record is mixed and disease-specific. Membrane and animal studies support cardiolipin-centered hypotheses; the human program includes both negative randomized outcomes and a narrow strength signal in Barth syndrome.

Forzinity's accelerated approval is real, current, and limited. It should neither be minimized as no approval nor inflated into a universal endorsement of SS-31, mitochondrial claims, or research-market vials. Reliable due diligence keeps chemical identity, mechanistic evidence, disease-specific human outcomes, product-specific regulation, and lot-specific supplier documentation separate.